Bioresorbable vascular scaffolds for small vessels coronary disease: The BVS-save registry

Catheterization and Cardiovascular Interventions

Volumn 88, Issue 3, 2016, Pages 380-387

  Latini, Roberto Adriano ^a   Granata, Francesco ^b   Ielasi, Alfonso ^c   Varricchio, Attilio ^b   Moscarella, Elisabetta ^b   Tespili, Maurizio ^c   Cortese, Bernardo ^a  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b Azienda Ospedaliera di Nola   (Italy)

^c BOLOGNINI HOSPITAL   (Italy)

Author keywords

BVS; overlapping BVS; small vessels

Indexed keywords

ADULT; AGED; ANGIOGRAPHY; ARTERY DIAMETER; ARTICLE; BIORESORBABLE SCAFFOLD; BIORESORBABLE VASCULAR SCAFFOLD; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY DISEASE; DEVICE ORIENTED CLINICAL OUTCOME; DISEASE REGISTRY; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HOSPITALIZATION; HUMAN; INTRAVASCULAR ULTRASOUND; ITALIAN (CITIZEN); LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPTICAL COHERENCE TOMOGRAPHY; PERCUTANEOUS CORONARY INTERVENTION; RETROSPECTIVE STUDY; SMALL CORONARY ARTERY; SMALL VESSEL CORONARY ARTERY DISEASE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; TARGET LESION REVASCULARIZATION; THROMBOLYSIS IN MYOCARDIAL INFARCTION; THROMBOSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 84986910161     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26516     Document Type: Article

References (27)

1. Foley DP, Melkert R, Serruys PW. Influence of coronary vessel size on renarrowing process and late angiographic outcome after successful balloon angioplasty. Circulation 1994;90:1239–1251.
2. Morice MC. Stenting for small coronary vessels. J Invasive Cardiol 2003;15:377–379.
3. Elezi S, Dibra A, Mehilli J, Pache J, Wessely R, Schömig A, Kastrati A. Vessel size and outcome after coronary drug-eluting stent placement: Results from a large cohort of patients treated with sirolimus- or paclitaxel-eluting stents. J Am Coll Cardiol 2006;48:1304–1309.
4. Hermiller JB, Fergus T, Pierson W, Su X, Sood P, Sudhir K, Stone GW. Clinical and angiographic comparison of everolimus-eluting and paclitaxel-eluting stents in small coronary arteries: A post hoc analysis of the SPIRIT III randomized trial. Am Heart J 2009;158:1005–1010.
5. Cortese B, Bertoletti A, De Matteis S, Danzi GB, Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: A meta-analysis of randomised and observational clinical studies with mid-term follow up. Int J Cardiol 2012;161:73–82.
6. Serruys PW, Garcia-Garcia HM, Onuma Y. From metallic cages to transient bioresorbable scaffolds: Change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 2012;33:16–25b.
7. Ormiston JA, Serruys PW, Regar E, Dudek D, Thuesen L, Webster MW, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial. Lancet 2008;371:899–907.
8. Serruys PW, Ormiston JA, Onuma Y, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-Year outcomes and results from multiple imaging methods. Lancet 2009;373:897–910.
9. Gomez-Lara J, Garcia-Garcia HM, Onuma Y, Regar E, Gonzalo N, Garcia-Garcia HM, Nieman K, Bruining N, Dorange C, Miquel-Hébert K, Veldhof S, Webster M, Thuesen L, Dudek D. A comparison of the conformability of everolimus-eluting bioresorbable vascular scaffolds to metal platform coronary stents. JACC Cardiovasc Interv 2010;3:1190–1198.
10. Diletti R, Farooq V, Girasis C, Bourantas C, Onuma Y, Heo JH, Gogas BD, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn RJ, Smits P, Koolen J, Meredith I, Li X, Miquel-Hebert K, Veldhof S, Garcia-Garcia HM, Ormiston JA, Serruys PW. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: Does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial. Heart 2013;99:98–105.
11. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, Caramanno G, Naber C, Di Mario C, Colombo A, Capranzano P, Wiebe J, Araszkiewicz A, Geraci S, Pyxaras S, Mattesini A, Naganuma T, Münzel T, Tamburino C. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: Early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention 2015;10:1144–1153.
12. Ielasi A, Cortese B, Varricchio A, RAI registry investigators. Immediate and midterm outcomes following primary PCI with bioresorbable vascular scaffold implantation in patients with ST-segment myocardial infarction: Insights from the multicentre “Registro ABSORB Italiano” (RAI registry). EuroIntervention 2015;11:157–162.
13. Cortese B, Ielasi A, Romagnoli E, Varricchio A, Cuculo A, Loi B, Pisano F, Corrado D, Sesana M, La Vecchia L, Summaria F, Tespili M, Silva Orrego P, Tognoni G, Steffenino G. Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions. Am J Cardiol 2015;116:705–710.
14. Nakatani S, Onuma Y, Ishibashi Y, Muramatsu T, Iqbal J, Zhang YJ, van Geuns RJ, Ormiston JA, Serruys PW. Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. EuroIntervention 2015;10:1288–1298.
15. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW, Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007;115:2344–2351.
16. Schunkert H, Harrell L, Palacios IF. Implications of small reference vessel diameter in patients undergoing percutaneous coronary revascularization. J Am Coll Cardiol 1999;34:40–48.
17. Elezi S, Kastrati A, Neumann FJ, Hadamitzky M, Dirschinger J, Schömig A. Vessel size and long-term outcome after coronary stent placement. Circulation 1998;98:1875–1880.
18. Biondi-Zoccai G, Moretti C, Abbate A, Sheiban I. Percutaneous coronary intervention for small vessel coronary artery disease. Cardiovasc Revasc Med 2010;11:189–198.
19. Sanchez OD, Yahagi K, Koppara T, Virmani R, Joner M. The everolimus-eluting Xience stent in small vessel disease: Bench, clinical, and pathology view. Med Devices (Auckl) 2014;8:37–45.
20. Hermiller JB, Rutledge DR, Mao VW, Zhao W, Wang J, Gruberg L, Lombardi W, Sharma SK, Krucoff MW. Clinical outcomes in real-world patients with small vessel disease treated with XIENCE V® everolimus-eluting stents: One year results from the XIENCE V® USA condition of approval post-market study. Catheter Cardiovasc Interv 2014;84:7–16.
21. Caputo R, Leon M, Serruys P, Neumann FJ, Yeung A, Windecker S, Belardi JA, Silber S, Meredith I, Widimský P, Saito S, Mauri L. Performance of the resolute zotarolimus-eluting stent in small vessels. Catheter Cardiovasc Interv 2014;84:17–23.
22. Honda Y, Fitzgerald PJ. Stent expansion as a mechanical parameter to predict late stent patency: Back to the basics. JACC Cardiovasc Interv 2009;2:1276–1278.
23. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, Litt MR, Kini A, Kabour A, Marx SO, Popma JJ, McGreevy R, Zhang Z, Simonton C, Stone GW, ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med 2015;373:1905–1915.
24. Woudstra P, Grundeken MJ1, Kraak RP1, Hassell ME, Arkenbout EK, Baan J, Jr, Vis MM, Koch KT, Tijssen JG, Piek JJ, de Winter RJ, Henriques JP, Wykrzykowska JJ. Amsterdam Investigator-initiateD Absorb strategy all-comers trial (AIDA trial): A clinical evaluation comparing the efficacy and performance of ABSORB everolimus-eluting bioresorbable vascular scaffold strategy vs. the XIENCE family (XIENCE PRIME or XIENCE Xpedition) everolimus-eluting coronary stent strategy in the treatment of coronary lesions in consecutive all-comers: Rationale and study design. Am. Heart J 2014;167:133–140.
25. Godino C, Furuichi S, Latib A, Morici N, Chieffo A, Romagnoli E, Tamburino C, Barbagallo R, Cera M, Antoniucci D, Goktekin O, Di Mario C, Reimers B, Grube E, Airoldi F, Sangiorgi GM, Colombo A. Clinical and angiographic follow-up of small vessel lesions treated with paclitaxel-eluting stents (from the TRUE Registry). Am J Cardiol 2008;102:1002–1008.
26. Farooq V, Serruys PW, Heo JH, Gogas BD, Onuma Y, Perkins LE, Diletti R, Radu MD, Räber L, Bourantas CV, Zhang Y, van Remortel E, Pawar R, Rapoza RJ, Powers JC, van Beusekom HM, Garcìa-Garcìa HM, Virmani R. Intracoronary optical coherence tomography and histology of overlapping everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: The potential implications for clinical practice. JACC Cardiovasc Interv 2013;6:523–532.
27. Farooq V, Onuma Y, Radu M, Okamura T, Gomez-Lara J, Brugaletta S, Gogas BD, van Geuns RJ, Regar E, Schultz C, Windecker S, Lefèvre T, Brueren BR, Powers J, Perkins LL, Rapoza RJ, Virmani R, García-García HM, Serruys PW. Optical coherence tomography (OCT) of overlapping bioresorbable scaffolds: From benchwork to clinical application. EuroIntervention 2011;7:386–399.